Variation Bio gets $35.7M funding for vaccine platform
Canada's Variation Biotechnologies (VBI), a privately-held biopharmaceutical company focused on the development of vaccines for infectious diseases using a novel platform technology, has secured $35.7 million in a series A financing. VBI will use the proceeds to advance the company's Variosite vaccine platform into clinical development, beginning with lead vaccine candidates for influenza.
The company was previously funded by private investors and leveraged with grants as well as other non-dilutive funding from the National Research Council of Canada's Industrial Research Assistance Program, Economic Development Canada and Investissement Quebec for a total of $2.1 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze